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Effects of PCV chemotherapy
on oligodendrogliomas and oligoastrocytomas
Pawe∏ Sokal, Jerzy Tujakowski1, Marek Harat, Andrzej Lebioda2
Several reports published in the recent years have proven the efficacy of chemotherapy in recurrent forms of low- and high-grade
oligodendrogliomas and oligoastrocytomas. The aim of this study was to evaluate the effects of the PCV chemotherapy
regime (procarbazine, lomustine, vincristine) in oligodendrogliomas and mixed tumours, to compare treatment results in
various groups of patients, to estimate progression-free survival and to identify prognostic factors for progression-free survival.
We applied Macdonald’ s criteria for assessing response of supratentorial gliomas to chemotherapy in second phase trials.
Between the years 1999 and 2003 we performed an analysis of 29 patients. Median time to progression for all patients was 16
months. We observed the following results of chemotherapy without previous surgical treatment: complete response lasting 8
months in a patient after stereotactic biopsy (CR) – 1 (3.4%), partial response (50% tumour regression lasting 9 months) (PR)
– 1 (3.4%) and minor response (MR) lasting 19, 26 and 16 months in 3 cases. 17 patients were found to have stable
disease. In 7 cases disease progression (PD) was observed with a median time to progression of 5 months. We found no
statistically significant differences between time to progression and age, sex, performance status measured in KPS, pathological
diagnosis, tumour laterality within the brain hemispheres and central area and steroid therapy both in univariate and
multivariate tests. The only statistically significant factor predicting the length of time to progression was the number of
chemotherapeutical cycles. Non-certain statistical significance was achieved in case of previous teleradiotherapy and character
of tumour. Chemotherapy was generally well tolerated. In 5 cases we observed myelotoxicity in grade 3; in 2 cases – in grade
4. Our results indicate that some oligodendrogliomas and mixed tumours may respond to PCV chemotherapy.
Ocena efektów chemioterapii wed∏ug schematu PCV
u pacjentów ze skàpodrzewiakami i skàpodrzewiakogwiaêdziakami
Badania opublikowane w ciàgu ostatnich lat wskazujà na skutecznoÊç chemioterapii w nawrotowej postaci skàpodrzewiaków
anaplastycznych, skàpodrzewiaków w niskim stopniu z∏oÊliwoÊci i guzach mieszanych. Celem pracy by∏a ocena skutecznoÊci
chemioterapii wed∏ug standardowego schematu PCV (prokarbazyna, lomustyna – CCNU, winkrystyna) u pacjentów
z rozpoznanym guzem mózgu o charakterze skàpodrzewiaka lub guza mieszanego skàpodrzewiako-gwiaêdziaka.
Wykorzystano kryteria odpowiedzi na leczenie glejaków nadnamiotowych dla badaƒ II fazy, ustalone przez Macdonalda.
Analizie poddano grup´ 29 pacjentów. Mediana czasu prze˝ycia wolnego od progresji dla wszystkich pacjentów wynosi 16
miesi´cy. Bioràc pod uwag´ efekty chemioterapii uzupe∏niajàcej PCV, nie uwzgl´dniajàce efektów leczenia operacyjnego,
ca∏kowità odpowiedê (CR) trwajàcà 8 miesi´cy stwierdzono u 1 pacjentki po biopsji stereotaktycznej, u której guz uleg∏
ca∏kowitej regresji, cz´Êciowà odpowiedê (PR) u 1 pacjenta z wynikiem czasu wolnego od progresji równym 9 miesi´cy.
Mniejszà odpowiedê (MR) z wynikami czasu wolnego od progresji 19, 26 i 16 miesi´cy stwierdzono w trzech przypadkach, 17
pacjentów opisano jako stan stabilny (SD). W 7 pozosta∏ych przypadkach zaobserwowano progresj´ choroby (PD) z wynikiem
mediany czasu wolnego od progresji 5 miesi´cy.
Wykorzystujàc testy analizy dla wielu zmiennych oraz analiz´ porównawczà dla dwóch zmiennych nie znaleziono statystycznie
istotnej zale˝noÊci pomi´dzy wiekiem, p∏cià, jakoÊcià ˝ycia ocenionà w skali Karnofsky’ego, a rozpoznaniem
histopatologicznym, pó∏kulà mózgu, w której znajdowa∏ si´ guz, obecnoÊcià guza w obszarze Êrodkowym, sterydoterapià.
Istotnym statystycznie czynnikiem predykcyjnym, majàcym wp∏yw na d∏ugoÊç czasu wolnego od progresji, by∏a liczba cykli
chemioterapii, które chorzy ukoƒczyli (p=0,01). Tendencj´ w kierunku statystycznej znamiennoÊci stwierdzono w odniesieniu
do wczeÊniejszej radioterapii zewn´trznej (p=0,02 i log rank p=0,22) oraz w przypadku charakteru guza (p=0,02 i log-rank
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Introduction
Primary brain tumours comprise nearly 2% of all
neoplasms. Every year over 3000 new cases of intracranial
tumours are diagnosed in Poland and 17000 cases in
United States [1-3]. Gliomas may be divided into several
types, the most frequent being astrocytomas and oligoden-
drogliomas. Both of them may occur as tumours of low or
high grade of malignancy. High-grade gliomas develop
either as primary tumours or may transform from pre-
existing low-grade forms [4].
Oligodendroglial tumours are a distinct clinical-
pathologic entity, which cause a lot of interest due to
their exceptional chemosensitivity. They are rare and
represent between 5% and 20% of intracranial gliomas
[5, 6].
P r o g n o s i s
The survival time of patients with oligodendrogliomas
depends upon several factors, such as the grade of
malignancy, age, performance status, extent of resection
and postoperative radiation [6-8]. Recent studies have
proved that allelic loss of chromosome arms 1p and 19q
might be a marker of better prognosis and chemosen-
sitivity [5]. Low-grade oligodendrogliomas have good
prognosis [9, 10]. Recent reports present patients survi-
ving over 16 years after diagnosis [11]. Median survival
with low-grade mixed tumours is shorter than with
oligodendrogliomas [8, 12]. Patients with anaplastic
oligodendrogliomas survive longer than patients with
other malignant gliomas, which may arise from tumour
natural history or better reaction to treatment [9, 10].
Tr e a t m e n t  o f  o l i g o d e n d r o g l i o m a s
Surgery is the main treatment modality for intracranial
gliomas, as in oligodendrogliomas, where resection is the
standard initial mode of treatment. Surgery has cyto-
reductive value, improves postoperative treatment
(radiotherapy and chemotherapy), decreases steroid
dosage, reduces symptoms and prolongs survival [5, 13-
15]. In case of poorly differentiated tumours there is no
evident data indicating that gross resection is more
beneficial than subtotal [16].
Adjunctive radiation therapy is a necessity, although
it may produce numerous complications [13]. Application
of radiotherapy in low-grade oligodendroglioma has been
questioned [17, 18].
Several recent reports present an analysis of the
chemosensitivity of anaplastic oligodendrogliomas and
oligoastrocytomas [5, 19-31].
In comparison with other types of gliomas,
oligodendrogliomas respond to alkylating agents. The
PCV (procarbazine+lomustine +vincristine) regimen
has appeared to be effective in providing durable
responses in anaplastic or aggressive oligodendrogliomas.
The term “aggressive” stands for low or high-grade
tumours, with rim enhancement and causing neurological
symptoms [22]. In 1988 Cairncross and Macdonald have
reported a series of recurrent oligodendrogliomas
sensitive to the PCV regimen [20]. They have also
demonstrated the chemosensitivity of anaplastic and
aggressive oligodendroglioma to the PCV regimen [22].
In another paper Cairncross presents a nearly 75%
response rate to the PCV regimen in patients with
malignant oligodendroglioma [21]. In low–grade oligoden-
droglioma durable remissions with clinical improvement
have been observed [4, 26, 28]. Fortin recommends
chemotherapy as the initial postoperative mode of
treatment in oligodendrogliomas. Radiotherapy should
be reserved for anaplastic forms [5, 32], in case of which
chemotherapy and then radiotherapy with at least
a seven-day gap between are effective treatment mo-
dalities after the surgical procedure is completed [5]. It is
common opinion that oligodendrogliomas are the only
chemosensitive brain tumours and that in low-grade forms
systemic therapy may be administered in conjunction with
radiotherapy [13, 33]. The PCV regimen is not effective in
the management of anaplastic astrocytomas [34]. Kapelle
reports its administration in glioblastoma multiforme with
quite good tolerance [35]. The results of temozolomide
chemotherapy in recurrent forms of oligodendrogliomas
and oligoastrocytomas appear to be promising [36-38].
Oligodendrogliomas respond to this treatment
probably because they do not have 06-metylguanin-DNA-
metyltransferase (MGMT), which is a repairing enzyme.
Nitrosoureas alkylate DNA and this very damage may
be repaired by methyltransferaze [39].
T h e  P C V  r e g i m e n
The standard PCV regimen consists of 3 chemothera-
peutic agents administered altogether in 6 cycles with 8-
week gaps:
CCNU: Lomustin 110 mg/m2 orally day 1
PCB: Procarbazine/ 60mg/m2 orally day 8-21
VCR: Vincristine 1.4 mg/m2 iv <2 mg on day 8 and 29
Despite increased toxicity some clinicians prefer
intensified PCV (I-PCV) administered every 6 weeks in
higher doses [11, 13, 22, 40].
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p=0,33). U 5 pacjentów (17,2%) stwierdzono objawy 3 stopnia i u dwóch pacjentek (6,9%) objawy 4 stopnia toksycznoÊci
hematologicznej, g∏ównie w postaci leukopenii i trombocytopenii. Przedstawione badanie wskazuje, ˝e niektóre skàpodrzewiaki
i guzy mieszane mogà reagowaç na chemioterapi´ PCV.
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Aim
The aim of this study was to evaluate the effects of PCV
chemotherapy (procarbazine, lomustine, vincristine) in
oligodendrogliomas and mixed tumours, to compare the
results in various groups of patients, to estimate pro-
gression-free survival and identify the factors prognostic
for progression-free survival (e.g.: patient age, patient
sex, performance, tumour laterality, histopathologic
diagnosis, surgery, radiation therapy).
Material and methods
The study was initiated in July 1999. Of the 35 patients who
had been entered for analysis until January the 1st 2003, 6
patients (who had not completed cycle 2, or with whom contact
had been lost) were excluded from the analysis. Altogether we
analysed the cases of 29 patients (aged 26 – 67 years, median 38)
(Table I) with histologically confirmed oligodendrogliomas or
mixed oligoastrocytomas. In all cases the performance status
was good (a minimum of 70 points acc. to the Karnofsky scale);
there was no history of previous chemotherapy nor of any
neurological or psychiatric disorders, blood cell count
parameters were stable: white blood count >3.000; platelets
>100.000/mm3; haemoglobin >10 g/dl.
Table I. Clinical characteristics










KPS = 80-100 25 86.2%
KPS< 80 4 13.8%
Previous treatment Teleradiotherapy 12 41.4%
Brachytherapy 6 20.7%
Surgery in reccurence 6 20.7%
Gross resection 4 13.8%
Subtotal resection 14 48.3%
Biopsy 16 55.2%
Histopathology Oligodendroglioma II° 14 48.3%
Oligoastrocytoma II° 4 13.8%
Oligodendroglioma III° 8 27.6%
Oligoastrocytoma III° 3 10.3%
Neurological deficits as dominant symptoms were observed
in 14 cases (48.3%), epilepsy in 23 cases (79.3%). The
histological diagnoses were as follows: 14 oligodendrogliomas
(48.3%), 8 anaplastic oligodendrogliomas (27.6%), 4 oligoastro-
cytomas (13.8%) and 3 anaplastic oligoastrocytomas. 14 (48.3%)
patients had completed all 6 cycles, 2 (6.9%) patients had
completed 2 and 4 cycles only due to myelotoxicity, 3 (10.3%)
patients died before the 4th cycle.
In 9 cases (31%) PCV chemotherapy was the single initial
therapeutic modality after stereotactic biopsy, in another 8 cases
(27,6%) it was administered after surgery as neoadjuvant
chemotherapy without previous radiotherapy.
We evaluated the clinical and radiological status (MRI,
CT) after every other clinical cycle, while the SPECT scans were
obtained before the 1st and after the 4th and 6th cycle.
C r i t e r i a  o f  r e s p o n s e  t o  c h e m i c a l
t r e a t m e n t
Evaluation of response was based on performance, neurological
and clinical status and radiological findings (enhanced CT or
MRI scans). Response was graded according to Macdonald’s
criteria for phase II studies of supratentorial gliomas based on
largest perpendicular area of enhancement of the tumour [23,
41-44]:
CR: Complete response – no tumour in enhanced scans, no
steroids, neurologically stable or improved.
PR: Partial response – >50% decrease in tumour size, stable or
reduced dose of steroids, neurologically stable or improved
MR: Minor response – 25%-50% decrease in tumour size, stable
or reduced dose of steroids
SD: Stable disease – no change or <25% change in tumour
size, stable or reduced dose of steroids, neurologically
stable, improved or deteriorated
PD: Progressive disease – >25% increase in tumour size or
new enhancement area, stable or increased dose of steroids,
stable or deteriorated neurological status.
S t a t i s t i c a l  a n a l y s i s
Time to progression was counted from the start of chemotherapy
to the day of progression or death. Progression-free survival
was estimated acc. to the Kaplan-Meier method. Univariate
analyses were performed using the log-rank test and multivariate
analyses using Cox’s proportional hazard model. We assumed
p≤0.05 to be statistically significant [45].
Results
The shortest observed time to progression was 3 months,
the longest – 26 months, median time to progression for
all patients was16 months (Figure 1). As for effects of
chemotherapy without previous surgical treatment the
following results were achieved: complete response lasting
8 months after stereotactic biopsy (CR) – 1 (3.4%)
(Figures 8, 9) partial response (50% tumour regression
lasting 9 months) (PR) – 1 (3.4%). Minor response (MR)
lasting 19, 26 and 16 months – 3 (10.2%). 17 patients
(incl. 3 who had received chemotherapy after gross-total
resection without radiological evidence of tumour before
and after chemotherapy and with stable neurological
status) were qualified as stable disease. In 7 cases disease
progression (PD) was observed with median time to
progression of 5 months (Table II, Figure 2).
Table II. Results of PCV chemotherapy
Response N % MTP
months
CR 1 3.4 -
PR 1 3.4 -
MR 3 10.3 -
SD 17 58.6 32.0
PD 7 24.1 5.0
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Re s u l t s  o f  c h e m o t h e r a p y  i n  r e l a t i o n  t o
h i s t o p a t h o l o g i c a l  d i a g n o s i s
(Table III, Figure 3).
Table III. Results of chemotherapy in relation to histopathologic
diagnosis
Response N % MTP
months
OII 14 48.3 32
OIII 8 27.6 16
OAII 4 13.8 7
OAIII 3 10.3 19
Median time to progression was 32 months in oligo-
dendrogliomas, 16 months in anaplastic oligoden-
drogliomas, 7 months in mixed tumours and 19 months in
anaplastic mixed tumours.
P r o g n o s t i c  f a c t o r s
Both in multivariate and univariate analysis we found no
statistically significant correlation between progression
free survival and age (p=0.3), sex (p=0.54), performance
status (p=0.76), histopathological diagnosis (p=0.16),
brain hemisphere with tumour location (p=0.72),
presence of the tumour in central area of brain (p=0.13),
steroid therapy (p=0.12) and application of chemo-
therapy as the sole treatment after stereotactic biopsy
(p=0.82). Median time to progression for patients less
than 40 years of age was 19 months, while for patients
with KPS <80 points it was only 5 months. Statistical
significance was achieved in case of radiation therapy
(p=0.02) applied previously in patients referred for
chemotherapy. However, due to a certain lack of
complete observations median time to progression could
have not been counted in group of non-irradiated
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Figure 1. Kaplan-Meier cumulated progression-free survival rate. Median time to progression (16 months)
Figure 2. Kaplan-Meier progression-free survival rate in relation to response
patients, while in the group of irradiated patients it was 14
months – shorter than in the entire examined group
(Figure 4).
It is likely that gross total removal has significant
influence on progression free survival. However, neither
the median nor any statistical significance could have
been estimated due to the small number of cases
(Figure 6).
Tumour characteristic – primary or recurrent –
achieved statistical significance (p=0.02) acc. to a multi-
variate analysis using Cox’s proportional hazard model.
Median time to progression for primary tumours was 16
months in the entire group, while for patients with
recurrent tumours it was shorter – only 14 months.
However, this was not found to be statistically significant
in the univariate analysis using the log-rank test (p=0.33)
(Figure 5).
The one statistically significant factor affecting the
length of time to progression was the number of admini-
stered cycles of chemotherapy (p=0.01) (Figure 7).
Uncertain statistical significance was achieved in relation
to such factors as previous teleradiotherapy and recurrent
character of the tumour, which shortened the time to
progression.
To x i c i t y
Generally chemotherapy was well tolerated. In 5 patients
(17.2%) we observed grade 3, and in 2 patients (6.9%) –
grade 4 haematological toxicity (leucopoenia and throm-
bocytopoenia). In a number of patients we observed
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Figure 4. Kaplan-Meier progression free survival in relation to previous irradiation
Figure 3. Kaplan-Meier progression-free survival rate in relation to histopatologic diagnosis
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Figure 5. Kaplan-Meier progression free-survival rate in relation to character of the tumour
Figure 6. Kaplan-Meier progression-free survival rate after gross-total surgery
Figure 7. Kaplan-Meier progression-free survival rate after 2nd, 4th, 6th cycle of chemotherapy
discrete symptoms of myelotoxicity, but after haema-
tological normalization chemotherapy was continued. In
2 cases chemotherapy had to be discontinued due to
grade 4 toxicity. In 1 case we observed an eczematic
reaction to Natulan, in another case there was transient
transaminaze elevation.
Discussion
The presented results have been obtained in the course of
a phase II study, in which the use of the chemo-
therapeutical agent had been assessed on the basis of
clinical and therapeutical criteria of response. The efficacy
of the agent is expressed as the percentage of objective
responses (i.e. complete or partial responses) [14, 46]. In
the presented study the small number of patients and the
short observation time are an evident drawback, as they
would be in the case of other similar phase II trials.
The efficacy of PCV chemotherapy has not yet been
reported in Polish literature
In papers reporting the role of chemotherapy on
central nervous system tumours one can find no direct
relation between tumour response and progression-free
survival or overall survival. Several other factors can
influence survival – previous surgery, radiation therapy or
steroid therapy. These factors may affect the inter-
pretation of the results of radiological examinations.
Response criteria should include radiological scans,
neurological status assessment and steroid doses [13, 41,
43]. However, the most important mark of efficacy is time
to progression. There exists no direct correlation between
the category of response and time to progression [41]. In
patients who had undergone brachytherapy or teleradio-
therapy the effects of these modalities may be observed
during chemotherapy. Radiotherapy can decrease
permeability of brain vessels, which may be interpreted as
tumour regression in enhanced CT or MRI scans [13].
In 17 cases (58.6%) the PCV regimen was applied as
neoadjuvant chemotherapy, after stereotactic biopsy (9
cases – 31%) or tumour resection (8 cases – 27.6%), but
before radiation therapy. In 12 patients (41.4%) PCV
chemotherapy was administered as adjuvant treatment,
after surgery and radiation (9 cases – 32%) or stereotactic
biopsy and radiation (3 cases- 10.3%).
Four patients, who had undergone gross total
removal, had no radiological or neurological evidence of
tumour before chemotherapy. In 1 case progression of
disease was observed, in 3 other cases stable disease was
assessed, i.e. the effects of combined surgical and
chemical treatment were good and could have been
interpreted as complete response.
We presume that chemotherapy may control tumour
growth and slow down its progression, as well as provide
symptom relief. In one isolated case we observed a new
tumour area in SPECT, but without enhancement in CT
scans. It could have been considered to be disease
progression but acc. to the classical criteria of response to
chemical treatment only radiological scans are considered
eligible.
We have observed that low-grade mixed tumours
have a poorer response than low-grade oligodendroglio-
mas. Median progression-free survival for oligodendro-
gliomas (OII – 32 months) is longer than for oligoastro-
cytomas (OAII – 7 months). Several reports indicate that
oligodendrogliomas respond better to chemotherapy than
oligoastrocytomas [5, 22, 24]. Complete response was
observed in 1 patient with anaplastic oligodendroglioma
(Figures 8, 9). Minor response was achieved in 2 patients
after surgical treatment and in 1 patient after stereotactic
biopsy. In some patients we observed delayed radiological
response after clinical improvement. Decreases in
frequency of epileptic seizures and neurological deficit
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Figure 8. 40-years old female after stereotactic biopsy with anaplastic
oligodendroglioma before chemotherapy
Figure 9. The same patient after chemotherapy. Complete response
improvement were observed after the second or fourth
cycle of chemotherapy, but radiological regression much
later. These observations confirm that oligodendrogliomas
may react to chemical treatment with a certain delay.
Some clinicians administer PCV regimen prior to
irradiation thus allowing to evaluate the effects of
chemotherapy on the residual tumour. The objective
response ratio is higher in those recurrent oligodendro-
gliomas in which radioterapy had not been applied [31].
Acc. to Glass this regimen is more effective as an initial
mode of treatment before radiation therapy [23]. Theo-
retically, radiation decreases the permeability of the
blood-brain barrier, thus also affecting its penetration by
oncolytic drugs [31]. Kyritsis suggests the induction of
new mutations, which may lead to the development of
forms more aggressive and resistant to treatment [25].
19 patients (65.5%) had primary tumours; in 10
other patients chemotherapy was employed when
recurrence was observed. Disease progression was
observed in 40% of recurrent tumours and 16% of
primary ones. Complete response and partial response
was observed only in primary tumours. The character of
the tumour affected the duration of progression-free
survival; in case of recurrent tumours it was shorter –
only 14 months. Cairncross had reported better response
in recurrent anaplastic oligodendrogliomas than in
primary ones [20, 21], while Kyritisis had observed worse
results in primary anaplastic tumours [25]. Van den Bent
had achieved similar results in both groups [40].
Oligodendrogliomas and oligoastrocytomas require
surgical treatment. Chemotherapy and radiotherapy are
only adjunctive forms of treatment [4, 5, 16]. In 36%
patients after radiotherapy symptoms of dementia and
brain necrosis occur, while 20% patients after chemo-
therapy report hepatotoxic and hematotoxic side effects
[19]. Surgical treatment is safer – new neurological deficits
are observed only in 6% of patients [19].
Chemotherapy administered to patients with
relatively lengthy survival in the presence of residual
disease allows delaying radiation therapy, which is
potentially detrimental [4]. Low-grade oligodendro-
gliomas and oligoastrocytomas show no progressive
growth with stable neurological status for several years
[11]. The range of surgical resection has an important
impact on the time to progression [7]. In the reported
studies tumour resection affected time to progression,
although not significantly. Acc. to several reports the
effect of gross-total resection is obvious in low-grade
tumours [7, 10, 47]. Fortin has not reported any
differences as to the effects of chemotherapy in patients
after gross total resection, subtotal resection or biopsy
[5]. Surgical treatment has a decompressing effect and
decreases the amount of acquired genetic anomalies
leading to deceleration of anaplastic progression and
delay of recurrence. It provides better penetration of
chemotherapeutic agents.
In case of low-grade oligodendrogliomas chemo-
therapy may improve the neurological status and lengthen
time to progression [4, 26, 28]. In our studies median
time to progression in low-grade oligodendrogliomas
was the longest – 32 months, although in most of the
cases stable disease was observed. Complete response
was observed in one patient with anaplastic oligo-
dendroglioma located in the central area of the brain.
Chemotherapy has an effect in anaplastic and aggressive
oligodendrogliomas [21, 22].
Conclusions
1. Our results indicate that some oligodendrogliomas or
oligoastrocytmas may respond to PCV chemotherapy.
2. According to our study results the only statistically
significant factor predicting the length of survival until
progression was the number of cycles of chemotherapy.
Uncertain statistical significance was achieved by
previous teleradiotherapy and by the character of
tumour.
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